Pinotbio is a global leading biotech brand that specializes in novel anticancer treatments. With a revolutionary approach to cancer therapy, Pinotbio aims to transform today's curiosity into tomorrow's cure. The brand offers a range of innovative products and services that make a significant impact in the field of oncology.

Pinotbio's R&D team is at the forefront of medical advancements, developing cutting-edge technologies to overcome the limitations of traditional anticancer drugs. Their flagship product, PINOT-ADC™, is a next-generation ADC (Antibody-Drug Conjugate) platform that revolutionizes targeted therapy by delivering powerful therapeutic agents directly to cancer cells. Additionally, Pinotbio offers NTX-301, a best-in-class DNMT1 inhibitor that shows promising results in inhibiting tumor growth.

They also provide NTX-101, a first-in-class topical treatment that lowers intraocular pressure and protects the optic nerve. With significant achievements in their business portfolio, Pinotbio is committed to making a difference in the fight against cancer. They regularly share their progress, research, and press releases, gaining recognition for their expertise and dedication.

Choose Pinotbio for their groundbreaking ADC platform and their expertise in developing targeted anticancer therapies. Contact them today to learn more about their innovative solutions, contribute to their mission, or inquire about collaborations. Pinotbio is located in Suwon, Gyeonggi-do, South Korea, at 156 Gwanggyo-ro, Gwanggyo Business Center